Abstract. The peroxisome proliferator-activated receptor γ γ (PPARγ γ) is a nuclear transcription factor that controls the genes involved in metabolism and carcinogenesis. In the present study, we examined the alteration of gene expression in HCT-116 human colorectal cancer cells by PPARγ γ agonists: MCC-555 (5 μM), rosiglitazone (5 μM), and 15-deoxy-Δ 12,14 -prostaglandin J 2 (1 μM). The long-oligo microarray data revealed a list of target genes commonly induced (307 genes) and repressed (32 genes) by tested PPARγ γ agonists. These genes were analyzed by Onto-Express software and KEGG pathway analysis and revealed that PPARγ γ agonists are involved in cell proliferation, focal adhesion, and several signaling pathways. Eight genes were selected to confirm the microarray data by RT-PCR and real-time PCR, from which CSTA, DAP13, TAF12, RIS1, CDKN3 and MAGOH were up-regulated, and KLHL11 and NCOA2 were downregulated. This study elucidates the commonly induced genes modulated by tested PPARγ γ ligands involved in the different signaling pathways and metabolisms, probably mediated in a PPARγ γ-dependent manner in colorectal cancer cells and helps to better understand the pleiotropic actions of PPARγ γ ligands.
Introduction
The peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor family and are activated by agonists that directly bind transcription factors to regulate the target genes (1) . At present, three types of PPARs have been identified (PPARα, PPARß/δ and PPARγ γ), each with different functions, tissue distributions and activations. Among them, PPARγ γ is highly expressed in adipose and colon tissue, and marginally expressed in the heart, skeletal muscle and liver tissues (2) . The PPARγ γ activation by agonists regulates adipocyte differentiation and promotes lipid storage in mature adipocytes. The PPARγ γ agonists can also affect cell proliferation, differentiation, and apoptosis in a PPARγ γ-dependent and/or independent manner and thereby represent a potentially important therapeutic approach to cancer treatments (1) . Thus, many studies describe beneficial effects of the PPARγ γ agonists for treatment of different types of cancer (3) (4) (5) (6) (7) , including colorectal carcinoma (8, 9) .
Agonists of PPARγ γ include prostaglandins of the J series (PGJ 2 ); the synthetic antidiabetic thiazolidinediones, such as troglitazone (TGZ), rosiglitazone (RGZ), and MCC-555; and oxidative metabolites of polyunsaturated fatty acids. Both TGZ and PGJ 2 affect several pathways in a PPARγ γ-independent manner: TGZ induces the p53 pathway (10) , inhibits cholesterol biosynthesis (11) , inhibits translation initiation (12) , and promotes antioxidant function (13) , whereas PGJ 2 induces apoptosis (14) and affects signaling pathways including Erk1/2 and NF-κB (15) . We have also recently demonstrated that TGZ induces the early growth response gene (EGR-1) independently of PPARγ γ transcription factor activation (8) and that MCC-555 induces apoptosis in HCT-116 cells, independently of PPARγ γ (16) . Thus, the anti-cancer activity of the PPARγ γ agonists should be explored both dependently and independently at the levels of transcription in several cancer types.
The objective of this study was to investigate the pattern of genes commonly modulated by three PPARγ γ agonists (MCC-555, RGZ and PGJ 2 ) in human HCT-116 colorectal cancer cells. The long-oligo microarray was employed and the data revealed a list of target genes commonly induced by tested PPARγ γ agonists. The pattern of altered genes was evaluated by cluster analysis, and the commonly regulated genes were analyzed by ontology and signaling pathway analysis, to better understand the biological profiles involved in PPARγ γ dependency. In addition, common genes involved in up-regulation (307 genes) and down-regulation (32 genes) by PPARγ γ agonists were analyzed and were shown to play important roles in cell proliferation, apoptosis, cell adhesion, energy homeostasis, insulin metabolism and other signaling pathways. Eight genes were selected for further analysis, of which 6 displayed higher mRNA expression in PPARγ γ agonist-treated HCT-116 cells than in untreated control: (DAP13) 13 kDa differentiation-associated protein cystatin A (CSTA), NADH dehydrogenase 1 α subcomplex 12, 20 kDa TATA box binding protein (TBP)-associated factor (TAF12), Ras-induced senescence 1 (RIS1), cyclin-dependent kinase inhibitor 3 (CDKN3) and mago-nashi homolog (Drosophila) proliferation-associated (MAGOH). We also determined that two genes displayed down-regulation of mRNA expression: kelch-like 11 (KLHL-11) and nuclear receptor coactivator 2 (NCOA2). This study identified several human genes that were commonly expressed by PPARγ γ agonists in human colorectal cancer cells, and this report describes their possible cellular and physiological roles in PPARγ γ-dependent tumor growth.
Materials and methods
Cell lines. Human colorectal adenocarcinoma cell line HCT-116 was obtained from American Type Culture Collection (ATCC, Manassas, VA). The cells were maintained in McCoy's 5A modified medium supplemented with 10% fetal bovine serum, 100 IU penicillin, and 100 μg/ml streptomycin and grown in an atmosphere of 5% CO 2 at 37˚C.
-thiazolidinedione (MCC-555), rosiglitazone (RGZ) and 15-deoxy-Δ 12,14 -prostaglandin J 2 (PGJ 2 ) were purchased from Cayman Chemical Co. (An Arbor, MI). All other chemicals and reagents were purchased from Fischer Scientific, unless otherwise specified.
Plasmids, transient transfections and luciferase assay.
The tk-PPREx3-Luc reporter plasmid, a PPAR-dependent luciferase construct, was generously provided by Dr Ron M. Evans (Salk Institute, La Jolla, CA). All transfection experiments were performed using Lipofectamine reagent (Invitrogen Corp., Carlsbad, CA) according to the manufacturer's instructions. Briefly, HCT-116 cells were seeded 2x10 5 cells per well in 12-well tissue culture plates in complete media overnight. Then the cells were co-transfected with 0.5 μg tk-PPREx3-Luc reporter plasmid and 0.05 μg pRL-null plasmid. After 5-h transfection, the media were replaced with complete media overnight, and cells were treated with different PPARγ γ agonists (5 μM MCC-555, 5 μM RGZ, or 1 μM PGJ 2 ) for an additional 24 h. The luciferase assay was performed using the Dual-Glo luciferase assay kit (Promega Corp., Madison, WI) according to the manufacturer's protocol. Produced luminescence was measured by a luminometer (TD-20/20, Turner Designs, Sunnyvale, CA) and data were analyzed by the Student's t-test. The results at * p<0.05, ** p<0.01 and *** p<0.001 were considered statistically significant.
RNA isolation for microarray analysis.
HCT-116 cells were grown in 100-mm dishes (2x10 6 ) in complete media overnight, and then washed twice with PBS and treated with 5 μM MCC-555, 5 μM RGZ, or 1 μM PGJ 2 in serum-free media for an additional 24 h. Total RNA was isolated from treated cell samples using an RNeasy mini kit (Qiagen, Valencia, CA).
Microarray labeling and hybridization. HEEBO long-oligo microarray slides were purchased from Microarray Inc. (Nashville, TN) based on a probe set designed by Illumina (San Diego, http://www.illumina.com) and Stanford University. The HEEBO long-oligo set contains about 39,000 probes for exonic regions and alternative spliced transcripts. Total RNA (1 μg) was labeled for each sample with a SuperScript III Labeling Kit (Invitrogen) according to the manufacturer's instructions. The purified probes from both control and treated samples were mixed and hybridized with the long-oligo microarray using a microarray hybridization kit (Corning, Inc., Corning, NY) on a MAUI hybridization station (Bio Micro Systems Inc., Salt Lake City, UT) according to the manufacturer's instruction. Dye swap experiments were included to eliminate dye-specific bias. For each sample set of treated vs. control, the treated mRNA was first labeled with Cy5 and the control with Cy3. In the reverse experiment, the labeling dyes were swapped. The two labeling reactions and microarray hybridizations were performed in parallel. Considering the reverse labeling experiments, a total of two biological replicates and two technical replicates of the experiment were performed.
Microarray data processing. After hybridization, the microarray slides were washed and scanned in a GenePix 4000 scanner (Axon Instrument, Union City, CA), and the images were processed by GenePix Pro 4.0 software (Axon Instrument). The resultant file was analyzed with Bioconductor (http://www.bioconductor.org), where local background subtraction and lowess normalization were carried out for each microarray slide. The biological replicates and technical replicates were considered differently in the analysis. Linear models from the limma package of Bioconductor were applied to derive a p-value and average of logarithm 2-based ratio. Changes in gene expression pattern were considered statistically significant at * p<0.05. A ratio cut-off of 1.5 and degree of freedom higher or equal to two (represents the changes of gene expression on at least three slide replicates of same experiment) were included as quality controls. The ratio cut-off of 1.5 in gene expression was selected because the action of PPARγ γ agonists are diverse in gene profiles; so to obtain the list of genes that are commonly down-regulated, we had to decrease the cut-off to a 1.5-fold instead of a 2-fold change as is commonly adopted for microarray data analysis.
In order to evaluate the microarray quality, the M vs. A plot was generated as a scatter plot of log intensity ratios M = log 2 (R/G) vs. average log intensities A = log 2 (RxG)/2, where R and G represent the fluorescence intensities in the red (R) and green (G) channels, respectively. Scatter plots were generated to compare the signal strength between slides to evaluate the reproducibility of the experiments. Reverse transcription PCR. HCT-116 cells were grown in 60-mm dishes (1x10 6 ) in complete media overnight, and then washed twice with PBS and treated with MCC-555 (5, 10 and 50 μM), RGZ (5, 10 and 50 μM), or PGJ 2 (1, 2 and 10 μM) in serum-free media for an additional 24 h. Total RNA was isolated from treated cell samples using an RNeasy mini kit (Qiagen), and then cDNA was synthesized from 1 μg of total RNA using an iScript cDNA Synthesis kit (Bio-Rad, Hercules, CA) according to the manufacturer's protocols. Synthesized cDNA (1 μg) was then added to a 20 μl PCR reaction mixture (GoTaq Green Master Mix PCR Reaction Mixture, Promega, Madison, WI) with each set of gene-specific primers. The primer sequences are described in Table I in detail. The final PCR products were loaded to agarose gels and photographed under UV light. The experiments were repeated in three independent replicates. The densitometries of the captured images were evaluated by Scion Image Software (Frederick, MD), and were shown on the final chart with mean ± SE values for each treatment. The Student's unpaired t-test was used to analyze the statistical significance.
Quantitative real-time-PCR.
Complementary DNA samples were diluted into 10 ng/μl, 0.1 ng/μl and 0.01 ng/μl concentration series. Three replicates of real-time PCR experiments were performed for each concentration using an ABI 7000 Sequence Detection System from AB Applied Biosystems (Foster City, CA) with the ABsolute QPCR SYBR-Green mix (ABgene House, Epsom, UK). The primers for target genes were designed by Primer Express software (AB Applied Biosystems) and the primers sequences are listed in Table I . The gene for TATA binding protein (TBP) was used as an internal control. After the real-time PCR experiments, Ct numbers were extracted for both reference genes and target genes with auto baseline and manual threshold. Amplification efficiency for the reactions was estimated as described previously (17), and multiple regression models were used to derive point estimation of ΔΔCt, p-value, standard error and 95% confidence intervals with the SAS 9.1 programs provided (SAS Institute).
Statistical analysis. We used SAS 9.1 (SAS Institute) or Student's unpaired t-test to analyze the data. Results were considered statistically significant at * p<0.05, ** p<0.01 and *** p<0.001.
Results

Transcriptional activation of the PPARγ γ receptor by PPARγ γ agonists in HCT-116 cells.
Agonists of the PPARγ γ receptor are known to possess anti-diabetic, anti-inflammatory and anti-cancer effects. In our study, we used three PPARγ γ agonists: two from the synthetic family of thiazolidinediones (MCC-555 and RGZ), and one naturally occurring metabolite of arachidonic acid (PGJ 2 ) (Fig. 1A) . To confirm that all three tested compounds are able to activate PPARγ γ and transcribe genes containing PPARγ γ binding sites in HCT-116 cells, a reporter construct, tk-PPREx3-Luc, was transfected and treated with the indicated PPARγ γ agonists, and luciferase activity was measured. It has been reported that HCT-116 cells highly express PPARγ γ (18) . As shown in 
Transcriptional responses of PPARγ γ agonists in HCT-116 cells.
To examine the transcriptional responses of PPARγ γ agonists, gene expression patterns were compared in MCC-555-, RGZ-and PGJ 2 -treated HCT-116 cells using longoligo microarrays containing the HEEBO oligo set. In our experiments, the cells were treated with 5 μM MCC-555, 5 μM RGZ and 1 μM PGJ 2 for 24 h, and then total RNAs were isolated and processed for the microarray experiment as described in Materials and methods. Experiments for each treatment group were carried out in four replicates. Genes Table I . Primer sequences used for RT-PCR.
modulated by PPARγ γ agonists with statistical significance between the experimental groups (vehicle vs. treatments) were identified by SAS statistical software. Changes in gene expression patterns were considered statistically significant at p<0.05 if present in at least three replicates (degree of freedom 2). To evaluate the quality of microarray data, the M vs. A plot was generated to plot logarithm 2-based two color ratios against the logarithm 2-based two color signal strength multiples ( Fig. 2A) , indicating even distribution of downregulated and up-regulated genes across different signal intensities. Scatter plots were also generated to compare the signal strengths between slides to evaluate the reproducibility of the experiments and microarray data quality (data not 
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shown). Fig. 2B shows the hierarchical cluster analysis of the distance between genes regulated by PPARγ γ agonists. Interestingly, MCC-555 shows a unique pattern in gene expression, compared to that of RGZ and PGJ 2 . This result may support a previous report that MCC-555 is a dual agonist for PPARγ γ and PPARα, whereas RGZ and PGJ 2 are PPARγ γ-specific agonists (16) . As shown in Fig. 2C , microarray data showed that MCC-555 (5 μM) treatment up-regulated 1056 genes and down-regulated 699 genes, RGZ (5 μM) treatment up-regulated 6472 genes and down-regulated 6460 genes, and PGJ 2 (1 μM) treatment up-regulated 5105 genes and down-regulated 5150 genes. Our results demonstrated that many genes were affected by PPARγ γ agonists, suggesting that PPARγ γ agonists play a role in the regulation of numerous --------------------------------------------------------------------------------------------------- 
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signaling pathways in human colorectal cancer both in a PPARγ γ-dependent and independent manner. For further analysis, we focused on a group of genes commonly regulated by the tested PPARγ γ agonists: 307 genes were commonly up-regulated and 32 genes commonly down-regulated. The list of top 20 genes commonly altered by PPARγ γ agonists are shown in Tables II and III with fold changes (ratios) and significant p-values. These genes were significantly modulated by all tested PPARγ γ agonists, suggesting that alteration of these genes may act in a PPARγ γ-dependent manner.
RT-PCR analysis of selected genes modulated by PPARγ γ agonists.
We have examined the expression of selected genes by semi-quantitative reverse transcriptase (RT-PCR) in HCT-116 cells treated by MCC-555, RGZ and PGJ 2 for 24 h as described in Materials and methods. We checked six commonly induced and two commonly repressed genes from our microarray data, based on the highest induction, p-value, and potential involvement in tumorigenesis. The six up-regulated genes are CSTA, DAP13, TAF12, RIS1, CDKN3 and MAGOH. As shown in Fig. 3 , results of RT-PCR showed that the expression levels of these six genes increased in HCT-116 cells treated with the indicated PPARγ γ agonists and consistent with the result of microarray data. In addition, we selected two down-regulated genes from microarray data and confirmed their expression by RT-PCR. As shown in Fig. 4 , KLH11 and NCOA2 expression levels were suppressed by the indicated PPARγ γ agonists. However, we did not observe a significant reduction of these two genes in the presence of RGZ. Since RT-PCR is not sensitive enough to detect minute differences, we performed real-time PCR to confirm our microarray data for the down-regulation of gene expression. The real-time PCR results confirmed downregulation of the KLHL-11 and NCOA2 genes (Fig. 4C) . The PCR results are in general consistent with our microarray data, although RT-PCR results showed smaller differences than microarray data. Overall, these results confirmed that CSTA, DAP13, TAF12, RIS1, CDKN3 and MAGOH are induced by PPARγ γ agonists, whereas KLHL11 and NCOA2 are down-regulated by PPARγ γ agonists.
Biological profiles of PPARγ γ agonist-induced genes. The final pattern of altered genes was evaluated by cluster analysis (Fig. 2B) , and the commonly regulated genes were analyzed by ontology and signaling pathway analysis to better understand the biological phenomena involved in PPARγ γ dependency. Functional analysis of genes with a ≥1.5-fold change in expression (p<0.05 with degree of freedom 2) was performed using the Onto-Express software to identify biological process and molecular function categories affected by PPARγ γ agonists. The data analysis showed distribution of biological process (143 genes), molecular function (157 genes), and cellular component classes (144 genes) with involved genes regulated by PPAR agonists. In addition, molecular function classes were associated with antioxidant activity, binding, catalytic activity, enzyme regulator activity, signal transducer activity, structural molecular activity, transcriptional regulator activity and transporter activity. Furthermore, the functional importance of PPARγ γ-induced target genes was analyzed by Pathway Express Software and reflected in major KEGG pathways containing previously well-identified and established genes. As shown in Fig. 5 the pathways affected by PPARγ γ agonists were cell cycle (CHEK2, MDM2 and RBX1), cytokine-cytokine receptor interaction (IL18 and VEGFB), ubiquitin-mediated proteolysis (UBE2E1 and RBX1), phosphatidylinositol signaling system (INPP5D), insulin signaling pathway (INPP5D), Wnt signaling pathway (RBX1), TGF-ß signaling pathway (RBX1), focal adhesion (VEGFB), calcium signaling pathway (SLC25A4) and colorectal cancer pathway (APPL).
Discussion
Colorectal cancer is the third most common cancer and the third leading cause of cancer-related mortality in the United States according to the American Cancer Society. However, over the past decade, colorectal cancer incidence and mortality rates have decreased compared to other cancers, and it is believed that chemoprevention research on human colorectal cancer has significantly contributed to this reduced risk. It is well known that the use of non-steroidal antiinflammatory drugs (NSAIDs) decreases the risk of colorectal cancer and is very effective for chemoprevention. Data from our and other laboratories indicate that PPARγ γ agonists also induce apoptosis and have anti-tumorigenic effects in colorectal cancer (8, 9) . PPARγ γ agonists play a pivotal role in anti-tumorigenesis in a PPARγ γ-dependent and -independent manner (1), and that is why both pathways should be considered to investigate their roles. In this regard, our data may provide an up-to-date list of genes on which PPARγ γ agonists act in a PPARγ γ-dependent and -independent manner in human colorectal cancer cells. In our experiments, we used the HEEBO long-oligo set which contains about 39,000 probes for exonic regions, and the alternative spliced transcripts microarray screening technique to identify the genes and signaling pathways commonly regulated by three different PPARγ γ agonists in human HCT-116 colorectal adenocarcinoma cells. As shown in this study, the expression of several genes was modulated either positively (307) or negatively (32) by three PPARγ γ agonists in HCT-116 cells, suggesting that both activation and repression can play an important role of PPARγ γ agonists in tumorigenesis, cell growth and differentiation. MCC-555 treatment showed a unique pattern of gene expression with the least number of modified genes compared to the RGZ or PGJ 2 treatments (Fig. 2B and C) . One possible explanation is that MCC-555 also binds to PPARα and possesses distinct properties compared to other PPARγ γ agonists. Indeed, we have shown that MCC-555 increases tumor suppressor protein NAG-1 at the post-transctiptional level, whereas TGZ affects it at the transcriptional level (16) .
We have identified some of the genes that are growthrelated, or involved in tumor invasion, metastasis and apoptosis. Cystatin A or stefin A (CSTA) has been known to belong to family I of cysteine proteinase inhibitors, which are commonly down-regulated in many cancers. A large body of literature has accumulated to suggest that stefins correlate with malignancy of various murine and human tumors (19) , such as lung, gastric, brain, colorectal and malignant melanoma (20) . Cystatins act as tumor suppressor genes and positively relate with survival probability (21) . Our data showed that the CSTA gene was up-regulated by all tested PPARγ γ agonists, which can have a beneficial effect on the treatment of colorectal cancer. Another tumor-growth related gene, CDKN3, which belongs to the dual specificity protein phosphatase family, was identified as a cyclin-dependent kinase (Cdk) inhibitor. CDKN3 has been shown to interact with the dephosphorylated Cdk-2 kinase, and thus prevent its activation (22) . Our data indicate that all tested PPARγ γ agonists induced the expression of the CDKN3 gene, which may be a potential candidate for a colorectal cancer target gene to inhibit cell cycle progression.
Unlike the above-mentioned genes CSTA and CDKN3, MAGOH, TAF12, RIS1 and DAP13 genes are potentially new candidate genes associated with cancer. MAGOH is one of the eight PPARγ γ-regulated genes reported in this study, and its protein product is the human homolog of the Drosophila mago-nashi protein (23) . Magoh protein plays important roles in mRNA splicing functions in the nucleus and cytoplasm. Indeed, both null mutation in flies and disruption of mRNA by RNAi in C. elegans show embryonic lethality, indicating that magoh is essential for viability (24) . In our study, the expression of the MAGOH gene was up-regulated in human HCT-116 colorectal cancer cells; however, its exact biological function and regulation by PPARγ γ agonists in colorectal cancer remains to be elucidated. In contrast, little is known about DAP13 [also known as NADH dehydrogenase (ubiquinone) 1 α subcomplex 12, NDUFA12], except that it is described as a theoretical product of a gene identified in a lung adenocarcinoma cell line that had been induced to differentiate by treatment with all trans-retinoic acid (25) .
Colorectal tumors develop mostly through several pathways, which are characterized by mutations in several suppressor genes (APC, SMAD and TP53) and oncogenes (KRAS2, MYC) and in chromosome instability. Ras-induced senescence 1 (RIS1) is a novel gene identified by Barradas et al (26) , and is up-regulated in association with Ras senescence. The RIS1 gene is located at chromosomal position 3p21.3, previously defined for its tumor-suppressor activity (27) ; this region frequently exhibits the loss of heterozygosity in tumors, which is what confers this gene a putative role as a tumor suppressor. Moreover, mutations in the RIS1 gene are associated with a worse prognosis and development of metastasis in colorectal tumors (28) . Another gene regulated by PPARγ γ agonists is TAF12 RNA polymerase II, a TATA box binding protein (TBP)-associated factor, which is an important part of the protein complex controlling the transcription by RNA polymerase II, and controlling the cell cycle and apoptosis (29) . It has been shown that TAF12 interacts with ATF7, a transcription factor, and that this interaction can be modulated by another TAF protein, TAF4 (30) .
Other genes characterized in our study are KLHL11 and NCOA2 that are down-regulated by PPARγ γ agonists. KLHL11 is the human ortholog of the identified zebrafish gene, kelchlike (klhl), an important gene involved in embryogenesis. The human KLHL gene is specifically expressed in the muscles and heart, which suggests a role in muscle cytoarchitecture (31) . Our microarray data also showed the down-regulation of nuclear receptor co-activator 2 gene, NCOA2, which is a family member of p160 kDa proteins involved in regulation of nuclear receptors, such as estrogen receptors and androgen receptors (32) . It has been reported that NCOA2 and other cofactors including SRC-1, p300/ CBP, and Tip60 are up-regulated in advanced prostate cancer (32) , suggesting that suppression of its expression is beneficial to prostate and other cancers.
Co-activators and co-repressors modulate the activity of PPARγ γ with influence on tumor formation. The pattern of commonly PPARγ γ agonist-altered genes were analyzed using the Onto-Express software, and signaling pathway analysis by Pathway Express Software was done to reflect the major KEGG pathways to better understand the biological phenomena involved in PPARγ γ dependency (Fig. 5) . However, KEGG pathway analyses were not able to recognize the new genes involved in well established signaling pathways. Microarray data and ontology report analysis showed that PPARγ γ plays an important role in cellular processes, development, growth, physiological processes, regulation of biological process, response to stimulus, antioxidant activity, binding, catalytic activity, enzyme regulator activity, signal transducer activity, structural molecular activity, transcriptional regulator activity and transporter activity.
A better understanding of the PPARγ γ receptor and its molecular signaling pathway opens up new therapeutic prospects in treatment of colorectal cancer. Our microarray data of PPARγ γ-induced genes showed that PPARγ γ agonists induced pleiotropic effects on the transcriptional program of human colorectal adenocarcinoma cells, involving metabolic (e.g., amino acid and lipid metabolism) and hormonal (e.g., sterol biosynthesis), cell organization, and regulatory pathways (e.g., cytoskeletal proteins). This raises the possibility that these additional mechanisms might contribute to the anti-cancer activity of nuclear receptor agonists, perhaps in a tumor-specific and tissue-specific manner. From all of the above, it is clear that the influence of PPARγ γ on cell cycle proliferation, differentiation and apoptosis is complex. These effects depend on the concentrations of agonists, the cell type, and/or the mutational events that predispose cancer development. The full understanding of the mechanisms requires additional laboratory studies to address the role of PPARγ γ in tumorigenesis.
